Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?

被引:26
|
作者
Calabresi, Paolo [1 ,2 ]
Standaert, David G. [3 ]
机构
[1] Univ Perugia, Santa Maria della Misericordia Hosp, Dept Med, Neurol Clin, I-06132 Perugia, Italy
[2] IRCCS Fdn Santa Lucia, Rome, Italy
[3] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA
基金
美国国家卫生研究院;
关键词
Dystonia; Dyskinesia; Levodopa; Basal ganglia; Cerebellum; Dopamine; Acetylcholine; Plasticity; DOPA-INDUCED DYSKINESIA; DEEP BRAIN-STIMULATION; BIDIRECTIONAL SYNAPTIC PLASTICITY; STRIATAL CHOLINERGIC INTERNEURONS; ASPARTATE GLUTAMATE RECEPTORS; IN MOUSE MODEL; BASAL GANGLIA; MOVEMENT-DISORDERS; GLOBUS-PALLIDUS; MODULATION;
D O I
10.1016/j.nbd.2019.104579
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dystonia and levodopa-induced dyskinesia (LID) are both hyperkinetic movement disorders. Dystonia arises most often spontaneously, although it may be seen after stroke, injury, or as a result of genetic causes. LID is associated with Parkinson's disease (PD), emerging as a consequence of chronic therapy with levodopa, and may be either dystonic or choreiform. LID and dystonia share important phenomenological properties and mechanisms. Both LID and dystonia are generated by an integrated circuit involving the cortex, basal ganglia, thalamus and cerebellum. They also share dysregulation of striatal cholinergic signaling and abnormalities of striatal synaptic plasticity. The long duration nature of both LID and dystonia suggests that there may be underlying epigenetic dysregulation as a proximate cause. While both may improve after interventions such as deep brain stimulation (DBS), neither currently has a satisfactory medical therapy, and many people are disabled by the symptoms of dystonia and LID. Further study of the fundamental mechanisms connecting these two disorders may lead to novel approaches to treatment or prevention.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease
    Pouclet, Helene
    Derkinderen, Pascal
    Lebouvier, Thibaud
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (02) : 235 - 236
  • [2] "Cueing" for Levodopa-Induced Dyskinesias in Parkinson's Disease
    Schaeffer, Eva
    Linke, Gerd
    Berg, Daniela
    [J]. FRONTIERS IN NEUROLOGY, 2016, 7
  • [3] Management of levodopa-induced dyskinesias in Parkinson's disease
    Kashihara, Kenichi
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 (Suppl 5) : 27 - 31
  • [4] Management of levodopa-induced dyskinesias in Parkinson's disease
    Kenichi Kashihara
    [J]. Journal of Neurology, 2007, 254 : 27 - 31
  • [5] Levodopa-induced ocular dyskinesias in Parkinson's disease
    Linazasoro, G
    Van Blercom, N
    Lasa, A
    [J]. MOVEMENT DISORDERS, 2002, 17 (01) : 186 - 187
  • [6] Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments
    Bargiotas, Panagiotis
    Konitsiotis, Spyridon
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1605 - 1617
  • [7] Risk factors for levodopa-induced dyskinesias in Parkinson's disease
    Grandas, F
    Galiano, ML
    Tabernero, C
    [J]. JOURNAL OF NEUROLOGY, 1999, 246 (12) : 1127 - 1133
  • [8] Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
    Stathis, P.
    Konitsiotis, S.
    Tagaris, G.
    Peterson, D.
    [J]. MOVEMENT DISORDERS, 2011, 26 (02) : 264 - 270
  • [9] Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
    Metman, LV
    Del Dotto, P
    Natté, R
    van den Munckhof, P
    Chase, TN
    [J]. NEUROLOGY, 1998, 51 (01) : 203 - 206
  • [10] Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease
    Merims, D
    Ziv, I
    Djaldetti, R
    Melamed, E
    [J]. LANCET, 1999, 353 (9166): : 1764 - 1765